Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
BPC-157 vs TB-500
An educational, source-based comparison of BPC-157 and TB-500 — how each peptide works, what it's researched for, and what to know before going deeper.
Quick answer
BPC-157 and TB-500 are both research peptides studied in animal models of tissue repair, and neither is FDA-approved for human therapeutic use. They are frequently discussed together because their proposed mechanisms are complementary rather than duplicative.
BPC-157 is a synthetic pentadecapeptide derived from a sequence in human gastric juice. Preclinical work associates it with angiogenesis via VEGFR2 signaling, upregulation of growth-factor receptors at injury sites, and effects on gut mucosal integrity — which is why it appears most often in gastrointestinal and tendon-healing literature.
TB-500 is a synthetic fragment corresponding to the active region of thymosin beta-4, a naturally occurring actin-binding protein. Its studied mechanism centers on actin sequestration, cell migration, and reduced inflammatory signaling, with rodent and equine literature covering wound closure, cardiac tissue, and corneal repair.
Both are prohibited in sport by WADA, both lack human efficacy trials, and both sit outside the regulated pharmaceutical supply chain — so material sold to consumers has no verified identity or purity. Any discussion of combining them is hypothesis, not evidence.
A pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Research suggests it modulates the nitric oxide system, upregulates growth hormone receptors in injured tissue, and promotes angiogenesis (formation of new blood vessels) — mechanisms associated with accelerated tendon, ligament, muscle, and intestinal mucosa repair in preclinical models.
- Tendon-to-bone healing
- Ligament and muscle recovery
- Gastric ulcer protection
- Inflammatory bowel models
- Neuroprotection (rodent)
- • Human clinical trials are limited — most research is preclinical.
- • Not FDA-approved for human therapeutic use.
- • Quality, purity, and dosing of compounded peptides vary widely.
Synthetic fragment of Thymosin Beta-4 studied for tissue and vascular repair.
A synthetic peptide fragment of Thymosin Beta-4 (Tβ4). Research suggests it upregulates actin, promotes cell migration, angiogenesis, and modulates inflammation — supporting repair in muscle, tendon, cardiac, and corneal tissue models.
- Muscle and tendon repair
- Cardiac tissue recovery (preclinical)
- Corneal and dermal wound healing
- Hair follicle stem cell activation
- • Not FDA-approved; banned by WADA.
- • Most evidence is preclinical.
BPC-157 vs TB-500 at a glance
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Molecule type | Synthetic 15-amino-acid peptide (pentadecapeptide) from gastric juice sequence | Synthetic fragment of thymosin beta-4 (actin-binding protein) |
| Proposed mechanism | Angiogenesis via VEGFR2/eNOS signaling; growth-factor receptor upregulation; gut mucosal protection | Actin sequestration driving cell migration; reduced inflammatory cytokine signaling |
| Most-studied research areas | Tendon and ligament healing, gastrointestinal mucosal injury, NSAID-induced damage (rodent models) | Dermal wound closure, cardiac tissue repair, corneal healing (rodent and equine models) |
| Evidence maturity | Extensive rodent literature; no completed human efficacy trials | Preclinical plus limited early-phase human safety studies of thymosin beta-4 |
| Regulatory status | Research peptide — not FDA-approved; flagged in FDA compounding review | Research peptide — not FDA-approved |
| Routes used in research | Intraperitoneal, subcutaneous, and oral in animal studies | Intraperitoneal and subcutaneous in animal studies |
| Anti-doping status | Prohibited at all times (WADA S0) | Prohibited at all times (WADA S2) |
| Known unknowns | No validated human dosing, long-term safety, or pharmacokinetics | No validated human dosing; angiogenic potential warrants caution in oncology contexts |
Who researches which — and why
BPC-157 dominates the preclinical literature on gastrointestinal mucosal injury and tendon-to-bone healing, so it attracts researchers interested in localized soft-tissue repair and gut barrier models. Interest also comes from investigators studying NSAID-induced gastric damage in rodents. None of that translates into an established human protocol — the human evidence base is effectively empty.
TB-500 draws interest from wound-healing and regenerative-medicine researchers because its parent molecule, thymosin beta-4, has been through early-phase human safety work in dermal and corneal wound settings. The actin-binding mechanism makes it a candidate of interest in models where cell migration is rate-limiting. Its angiogenic activity is also the reason caution is repeatedly raised in oncology contexts.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
3 cited studies; evidence base is growing.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| BPC-157 | Pentadecapeptide BPC 157 and the central nervous system | Neural Regeneration Research | 2022 | Review of neuroprotective and neurorepair signaling pathways observed in animal models. |
| BPC-157 | Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia/reperfusion in rats | Journal of Physiology - Paris | 2018 | Demonstrated mucosal protective effects and accelerated recovery from induced colitis. |
| BPC-157 | BPC 157 and tendon-to-bone healing | Journal of Orthopaedic Research | 2010 | Improved biomechanical recovery of transected Achilles tendons in rats. |
| TB-500 | Thymosin beta-4: a multi-functional regenerative peptide | Expert Opinion on Biological Therapy | 2015 | Review of Tβ4's roles in repair, angiogenesis, and anti-inflammation. |
Side-effect & safety grid
- Human clinical trials are limited — most research is preclinical.
- Not FDA-approved for human therapeutic use.
- Quality, purity, and dosing of compounded peptides vary widely.
- Not FDA-approved; banned by WADA.
- Most evidence is preclinical.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
BPC-157 vs TB-500 — Key differences
- Class: BPC-157 is classified as Tissue Repair · Gastrointestinal, while TB-500 is Tissue Repair · Vascular.
- Primary research focus: BPC-157 — tendon-to-bone healing; TB-500 — muscle and tendon repair.
- Tag: Recovery vs Recovery.
BPC-157 Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Tendon and ligament recovery (preclinical) | Rodent models (rat, mouse) | Subcutaneous or intraperitoneal | 10 mcg/kg/day | 10–14 days in most cited studies | Animal data only; cited human-grade safety or efficacy evidence is not established. |
| GI mucosal recovery (preclinical) | Rodent models | Oral or intragastric in some studies; subcutaneous in others | 10–50 mcg/kg/day depending on study | 5–14 days | Frequently cited in gut-recovery literature; remains preclinical. |
| Anecdotal human research-use (non-clinical literature) | Adults, mixed; off-label | Subcutaneous | Commonly cited 250–500 mcg, 1–2× daily | 2–6 week cycles in user reports | Not validated by controlled human trials; FDA has flagged BPC-157 outside approved drug pathways. |
BPC-157 Research — Female vs Male Studies
How published BPC-157 research breaks down by sex, including which populations were studied and what trial data exist.
Female research
Female-specific clinical trial data for BPC-157 are essentially absent. Preclinical rodent studies have included female animals but do not isolate sex-based outcomes.
- Female rodents in tissue-recovery models
- • No published human RCTs stratified by sex.
- • Pregnancy, lactation, and hormonal-cycle effects have not been characterized.
Male research
Male-specific clinical data are similarly limited. Most cited animal studies use male rodents for tendon, ligament, and GI models.
- Male rodents in tendon/ligament/GI repair models
- • No published human RCTs in men.
- • Anecdotal human use reports skew male but do not constitute clinical evidence.
BPC-157 — Frequently Asked Questions
Is BPC-157 FDA-approved?+
No. BPC-157 is not FDA-approved for any indication. It has appeared on the FDA's bulk-substance review lists as not eligible for traditional compounding under current evidence.
What does research suggest BPC-157 is studied for?+
Most cited BPC-157 research involves rodent models of tendon, ligament, and gastrointestinal mucosal recovery. Human controlled trial data remain very limited.
Are BPC-157 protocols the same for men and women?+
Published literature does not separate BPC-157 dosing by sex. There are no controlled human trials establishing sex-specific protocols.
TB-500 Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Tissue and wound recovery (preclinical) | Rodent and large-animal models | Subcutaneous or intramuscular | Equivalent of ~2 mg/kg in some animal models | Single doses to multi-week courses across studies | Cited in preclinical recovery and angiogenesis literature. |
| Cardiac and dermal recovery research (early human work) | Small early-phase human studies of thymosin beta-4 | Topical (dermal ulcers) or IV (cardiac research) | Topical formulations 0.01–0.1% in ulcer studies | Several weeks in dermal-ulcer trials | Early-phase research only; not an FDA-approved drug. |
| Anecdotal injectable use (off-label) | Adults, mixed; off-label | Subcutaneous | Commonly cited 2.0–2.5 mg, 1–2× per week in non-clinical reports | 4–6 week 'loading' phases described in user reports | Banned by WADA in athletes; not a validated clinical protocol. |
TB-500 Research — Female vs Male Studies
How published TB-500 research breaks down by sex, including which populations were studied and what trial data exist.
Female research
Published TB-500 / thymosin beta-4 research includes both sexes in dermal-ulcer and cardiac pilot studies, but female-specific endpoints are not isolated.
- Mixed-sex early-phase human dermal-ulcer studies
- • Pregnancy and lactation data are not established.
- • No sex-stratified outcomes reported in the cited literature.
Male research
Male-specific clinical data for TB-500 are limited to mixed-sex early-phase studies. Anecdotal recovery use reports skew male but are not controlled research.
- Mixed-sex early-phase human studies
- • No male-only TB-500 RCTs identified in the cited literature.
- • WADA prohibits TB-500 in competitive athletes year-round.
TB-500 — Frequently Asked Questions
Is TB-500 the same as thymosin beta-4?+
TB-500 is the research name for a synthetic fragment closely related to thymosin beta-4 (TB-4), the naturally occurring 43-amino-acid peptide. The two terms are often used interchangeably in research literature, though formulations can differ.
Is TB-500 FDA-approved?+
No. TB-500 is not FDA-approved for any indication. Thymosin beta-4 has been studied in early-phase trials for dermal ulcers and cardiac recovery but is not an approved drug.
Why is TB-500 banned in athletes?+
TB-500 is on the World Anti-Doping Agency (WADA) prohibited list year-round as a non-specified prohibited substance, primarily on the basis of its tissue-recovery and angiogenic effects.
BPC-157 vs TB-500 — frequently asked questions
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid synthetic peptide derived from a gastric-juice protein sequence, studied mainly for angiogenesis and gastrointestinal and tendon repair in rodents. TB-500 is a synthetic fragment of thymosin beta-4 whose studied mechanism is actin sequestration and cell migration, with literature spanning dermal, cardiac and corneal wound models. Different origin, different proposed mechanism, overlapping research theme of tissue repair.
Are BPC-157 and TB-500 often researched together?
They are frequently discussed together because their proposed mechanisms are complementary — angiogenic signaling alongside cell migration. However, no controlled study has established a synergistic effect in humans, and combination discussion in the consumer space is speculation rather than a research finding.
Is either one FDA-approved?
No. Both are research peptides with no FDA approval for any human therapeutic indication. BPC-157 has additionally been reviewed by the FDA in the context of compounding, where it was not placed in the category permitting bulk compounding. Neither should be understood as a treatment.
Are they banned in competitive sport?
Yes, both. TB-500 falls under WADA's S2 category of peptide hormones and growth factors, and BPC-157 falls under S0 as a non-approved substance. Both are prohibited at all times, in and out of competition.
What safety concerns are raised in the literature?
The largest concern for both is the absence of human safety data — no established dosing, no pharmacokinetic profile, no long-term follow-up. Because both influence angiogenesis, caution is repeatedly raised regarding contexts where new blood-vessel formation is undesirable, including active malignancy. Product quality is a separate and serious issue, since neither is supplied through a regulated pharmaceutical channel.
How are they administered in published research?
Animal studies most commonly use intraperitoneal or subcutaneous injection, with some BPC-157 work also examining oral administration in rodents and drinking-water delivery. These are experimental designs in animals; they do not constitute a human protocol and cannot be scaled by body weight into one.
Which one is studied more for gut health?
BPC-157. Its origin sequence comes from human gastric juice, and the largest share of its preclinical literature covers gastric and intestinal mucosal injury, NSAID-induced damage, and inflammatory bowel models. TB-500's literature is concentrated in dermal, corneal, and cardiac repair instead.
Which one has more human data?
Neither has human efficacy data as sold. The closest signal belongs to TB-500's parent molecule, thymosin beta-4, which has been through early-phase human safety studies in wound-healing indications. BPC-157's human record is limited to small early-phase work cited in inflammatory bowel disease programmes.
How long do research protocols typically run?
Rodent studies most often run acute courses of days to about four weeks, matched to the injury model being measured. Longer exposure windows are rare in the published record, which is one reason no long-term safety picture exists for either peptide.
References
- Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology. 2016.
- Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease. Current Pharmaceutical Design. 2011.
- Pentadecapeptide BPC 157 enhances growth hormone receptor expression in tendon fibroblasts. Molecules. 2014.
- Thymosin beta-4 and cardiac repair. Annals of the New York Academy of Sciences. 2010.
- Thymosin beta 4 promotes dermal healing. Vitamins and Hormones. 2016.
- Thymosin beta 4 sequesters actin and promotes cell migration in wound repair. Annals of the New York Academy of Sciences. 2012.
- WADA Prohibited List — peptide hormones, growth factors and non-approved substances. World Anti-Doping Agency. 2025.
Educational information only. Nothing on this page is medical advice, a diagnosis, or a recommendation to use any compound. Investigational peptides are not available outside registered clinical trials. Discuss any therapy with a licensed clinician.